Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Completed
Cytogen Corporation
Phase 1
2003-03-01
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when
given in combination with hormonal and external beam radiation therapy in men with high risk
prostate cancer.
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Completed
Sidney Kimmel Cancer Center at Thomas Jefferson University
Phase 1
2003-03-01
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when
given in combination with hormonal and external beam radiation therapy in men with high risk
prostate cancer.
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Completed
National Cancer Institute (NCI)
Phase 1/Phase 2
2005-09-01
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry
radiation directly to cancer cells and not harm normal cells. Bortezomib may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood
flow to the cancer. Bortezomib may also make cancer cells more sensitive to radiation
therapy. Giving samarium Sm 153 lexidronam pentasodium together with bortezomib may kill more
cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when
given together with samarium Sm 153 lexidronam pentasodium and to see how well they work in
treating patients with relapsed or refractory multiple myeloma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
